Pharmaceuticals, Biotechnology and Life Sciences
– Week 24 Results Support Continued Development as a Potential Long-Acting Oral Combination Treatment Option in Virologically Suppressed People with…
Colossal scientists achieve global first; technology promises seminal advancements for engineering Woolly Mammoth phenotypes in in vitro cellular models, developmental…
COSTA MESA, Calif.–(BUSINESS WIRE)–Pyramid Labs, Inc. (“Pyramid” or the “Company”), a leader in drug product contract development and manufacturing with…
This latest extension of the award-winning campaign, aimed at introducing XEOMIN® (incobotulinumtoxinA) to a younger, toxin-naïve audience, also marks the…
DUBLIN–(BUSINESS WIRE)–The “Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials 2024” report has been added…
DUBLIN–(BUSINESS WIRE)–The “Duchenne Muscular Dystrophy – Global Clinical Trials Review, 2024” clinical trials has been added to ResearchAndMarkets.com’s offering. The…
CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the recent publication of preclinical data in the…
Combination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, third-line non-small cell lung cancer (NSCLC) ORR…
DUBLIN–(BUSINESS WIRE)–The “Non-Small-Cell Lung cancer (NSCLC) – Pipeline Insight, 2024” clinical trials has been added to ResearchAndMarkets.com’s offering. This report…
– Insertion of a functional OTC gene through ARCUS in vivo gene editing may provide lasting clinical benefit for children…